Medivir AB and Daewoong Pharmaceutical Co. Ltd. have decided to discontinue development of hepatitis B compound, MIV-210, based on a joint decision.   Under the collaboration Daewoong was responsible for R&D. While MIV-210 demonstrated competitive antiviral activity, like other drugs of this class, it did not completely eradicate HBV. Taking into consideration the commercial environment for HBV drugs, with the current standard of care approaching generic status, a robust cure profile is need...